This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be administered intravenously as monotherapy or in combination in participants with CD123 positive hematological malignancies.

Inclusion Criteria:

• ≥18 years of age;

• CD123+ hematologic malignancy based on flow cytometry or immunohistochemistry by local laboratory;

  • R/R AML (except APL);
  • R/R HR-MDS with ≥5% bone marrow blast at time of inclusion;

• Had at least 1 prior line of therapy at currents histology, and have no available treatment options;

• ECOG performance status of ≤ 2.

The above is a summary, other inclusion criteria details may apply.

Exclusion Criteria:

• Active CNS leukemia;
• Previous treatment with any CD123 targeting therapy;
• Prior allogeneic HSCT, within 90 or cell therapy within 60 of start of therapy;
• Active GVHD that requires immunosuppressive treatment within 4 weeks prior to start of AZD9829;
• History of other malignancy(with certain exceptions);
• Active and uncontrolled infections;
• Unresolved AEs ≥2 Grade, from prior therapies.

The above is a summary, other exclusion criteria details may apply .

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.